Edition:
India

Dechra Pharmaceuticals PLC (DPH.L)

DPH.L on London Stock Exchange

3,274.00GBp
4 Dec 2020
Change (% chg)

0.00 (+0.00%)
Prev Close
3,274.00
Open
3,338.00
Day's High
3,338.00
Day's Low
3,268.00
Volume
124,846
Avg. Vol
215,858
52-wk High
3,608.91
52-wk Low
2,030.00

Latest Key Developments (Source: Significant Developments)

Dechra Pharma Says Q1 Trading Stronger Than Expected
Tuesday, 27 Oct 2020 

Oct 27 (Reuters) - Dechra Pharmaceuticals PLC ::DECHRA PHARM PLC - ANNUAL GENERAL MEETING - TRADING UPDATE.DECHRA PHARMACEUTICALS PLC - TRADING IN Q1 OF FINANCIAL YEAR HAS BEEN STRONGER THAN EXPECTED.  Full Article

Dechra Pharma Says Trading In Year In Line With Management Expectations
Thursday, 9 Jul 2020 

July 9 (Reuters) - Dechra Pharmaceuticals PLC ::DECHRA PHARMACEUTICALS PLC - TRADING IN YEAR WAS ROBUST AND IN LINE WITH MANAGEMENT EXPECTATIONS.DECHRA PHARMACEUTICALS - FY REPORTED GROUP REVENUE FOR PERIOD INCREASED BY C.7% AT CONSTANT EXCHANGE RATE (CER) (C.7% AT ACTUAL EXCHANGE RATE (AER)).  Full Article

Dechra Pharma Says Trading To Most Likely Be Challenging Until Year End After "Record" March
Wednesday, 3 Jun 2020 

June 3 (Reuters) - Dechra Pharmaceuticals PLC ::CONFIRM THAT OUTLOOK FOR FULL YEAR 2020 IS BROADLY IN LINE WITH MANAGEMENT EXPECTATIONS.HAS MADE SIGNIFICANT PROGRESS WITH PREVIOUSLY DISCUSSED MANUFACTURING ISSUES, WITH IN-HOUSE SUPPLY ISSUES MOSTLY RESOLVED.NORTH AMERICA HAS RETURNED TO GROWTH, AS ANTICIPATED AT TIME OF HALF-YEAR RESULTS IN FEBRUARY.NET DEBT FOR YEAR ENDING 30 JUNE 2020 EXPECTED TO BE £386 MILLION..GROUP REVENUE FOR PERIOD INCREASED BY C.10.5% AT CONSTANT EXCHANGE RATES.TRADING AND WILL MOST LIKELY REMAIN CHALLENGING UNTIL YEAR END,.IN KEY MARKETS IN WHICH DECHRA OPERATES, MAJORITY OF VETERINARY PRACTICES ARE STILL OPERATING.GROUP EXPECTS TO INVEST C.£4.5 MILLION IN FY21 ON DEVELOPMENT OF AKSTON.BOARD REMAIN CONFIDENT OSURNIA ACQUISITION WILL BE CLEARED BY RELEVANT AUTHORITIES AND THAT IT WILL COMPLETE SHORTLY.DECHRA - IMPACT OF COVID-19 ON REVENUES IS DIFFICULT TO PREDICT, EXPECT THERE TO BE SOME STOCK UNWIND AT WHOLESALERS, SOME WEAKNESS IN DEMAND.AN UNDERSPEND ON PRODUCT DEVELOPMENT PIPELINE IN FY20 IS ANTICIPATED DUE TO COVID-19 RELATED DELAYS."RECORD MARCH" AS VETERINARIANS STOCKED UP ON ESSENTIAL MEDICINES.  Full Article

Dechra Acquires Worldwide Rights To Mirataz
Tuesday, 17 Mar 2020 

March 17 (Reuters) - Dechra Pharmaceuticals PLC ::DECHRA ACQUIRES WORLDWIDE RIGHTS TO MIRATAZ (R).TO BUY RIGHTS TO MIRATAZ FROM KINDRED BIOSCIENCES FOR USD43.0 MILLION AND A ROYALTY ON FUTURE SALES.ACQUISITION WILL BE FINANCED FROM GROUP'S EXISTING CASH AND BORROWING FACILITIES.DESPITE EQUITY MARKET CONDITIONS, CHANGING DEVELOPMENTS ON VIRUS, BUSINESS REMAINS ROBUST, STRONG BALANCE SHEET & CASH FLOW.  Full Article

Kindred Biosciences Announces Mirataz Transaction And Reports Q4 Results
Tuesday, 17 Mar 2020 

March 16 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES MIRATAZ® (MIRTAZAPINE TRANSDERMAL OINTMENT) TRANSACTION AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.DEAL FOR $43 MILLION.ENTERED INTO A TRANSACTION FOR SALE OF MIRATAZ TO DECHRA PHARMACEUTICALS PLC.WILL SUBSTANTIALLY REDUCE COMMERCIAL FOOTPRINT.KINDRED BIOSCIENCES - IN CONNECTION WITH STRATEGIC SHIFT, ELIMINATING ABOUT 53 POSITIONS, REPRESENTING ABOUT ONE-THIRD OF ITS CURRENT WORKFORCE.KINDRED BIOSCIENCES - PROCEEDS FROM MIRATAZ DEAL, ALONGSIDE REDUCTION IN CO'S WORKFORCE & OPERATIONS, TO EXTEND CASH RUNWAY THROUGH 2022.KINDRED BIOSCIENCES - WORKFORCE REDUCTION IS ANTICIPATED TO LOWER COMPENSATION AND BENEFITS COST BY APPROXIMATELY $7.1 MILLION ANNUALLY.Q4 LOSS PER SHARE $0.40.QTRLY NET PRODUCT REVENUES $1.4 MILLION VERSUS $1.3 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.36, REVENUE VIEW $1.3 MILLION -- REFINITIV IBES DATA.  Full Article

Dechra Pharma Says Prolonged Interruption In China From COVID-19 Would Lead To Co Being "Out Of Stocks"
Monday, 24 Feb 2020 

Feb 24 (Reuters) - Dechra Pharmaceuticals PLC ::DECHRA PHARMACEUTICALS PLC - HY OPERATING PROFIT 23.3 MILLION STG VERSUS 17 MILLION STG.DECHRA PHARMACEUTICALS PLC - DECLARE AN INTERIM DIVIDEND OF 10.29 PENCE PER SHARE.DECHRA - OUTLOOK FOR FULL YEAR REMAINS IN LINE WITH MANAGEMENT EXPECTATIONS, ALTHOUGH PERFORMANCE IN NORTH AMERICA WILL REMAIN CHALLENGING.DECHRA HY REVENUE 248.5 MILLION STG VERSUS 231.4 MILLION STG.DECHRA - ASSESSING POTENTIAL IMPACT ON GROUP OF COVID-19 VIRUS, IF ANY.DECHRA - HAVE NO DIRECT OR INDIRECT REVENUES IN CHINA AND CO HAS SUFFICIENT INVENTORY OF CHINESE SOURCED MATERIALS TO DEAL WITH NEAR TERM SUPPLY.DECHRA - PROLONGED PERIOD OF INTERRUPTION IN CHINA WOULD LEAD TO CO BEING "OUT OF STOCKS".  Full Article

Dechra Pharmaceuticals Says Co To Acquire Worldwide Rights To Osurnia Products
Monday, 6 Jan 2020 

Jan 6 (Reuters) - Dechra Pharmaceuticals Plc ::DECHRA PHARM PLC - DPH ACQUIRE WORLDWIDE RIGHTS TO OSURNIA PRODUCTS.ACQUISITION IS EXPECTED TO BE EARNINGS ENHANCING FOR FY ENDING 30 JUNE 2021, ASSUMING COMPLETION BEFORE END OF JUNE 2020.  Full Article

Dechra Pharmaceuticals Signs Private Placement Of Eur 50 Mln Seven Year Notes
Wednesday, 18 Dec 2019 

Dec 18 (Reuters) - Dechra Pharmaceuticals PLC ::DECHRA PHARMACEUTICALS PLC - SIGNING OF A PRIVATE PLACEMENT OF EUR50 MILLION SEVEN YEAR AND USD100 MILLION TEN YEAR NEW SENIOR UNSECURED NOTES.DECHRA PHARMACEUTICALS PLC - NOTES WILL BE ISSUED ON 22 JANUARY 2020, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.DECHRA PHARMACEUTICALS PLC - ISSUE HAS SIMILAR COVENANTS TO GROUP'S EXISTING FACILITIES.  Full Article

Dechra Pharma Names Paul Sandland As Permanent CFO
Wednesday, 30 Oct 2019 

Oct 30 (Reuters) - Dechra Pharmaceuticals PLC ::APPOINTMENT OF CHIEF FINANCIAL OFFICER.PAUL SANDLAND, ACTING CFO SINCE APRIL THIS YEAR, HAS BEEN APPOINTED AS EXECUTIVE DIRECTOR AND PERMANENT CFO.  Full Article

Dechra Pharmaceuticals Says Confident About FY Prospects
Friday, 18 Oct 2019 

Oct 18 (Reuters) - Dechra Pharmaceuticals PLC ::AGM TRADING UPDATE.REMAINS CONFIDENT ABOUT COMPANY'S PROSPECTS FOR CURRENT FINANCIAL YEAR.WORK CONTINUES TO RESOLVE SUPPLY ISSUES PREVIOUSLY HIGHLIGHTED WITH MANY OF THESE HAVING NOW BEEN MITIGATED.  Full Article

BRIEF-Dechra Pharma Says Trading In Year In Line With Management Expectations

* DECHRA PHARMACEUTICALS PLC - TRADING IN YEAR WAS ROBUST AND IN LINE WITH MANAGEMENT EXPECTATIONS